[go: up one dir, main page]

UA85099C2 - Liposomal irinotecan preparation - Google Patents

Liposomal irinotecan preparation

Info

Publication number
UA85099C2
UA85099C2 UAA200614105A UAA200614105A UA85099C2 UA 85099 C2 UA85099 C2 UA 85099C2 UA A200614105 A UAA200614105 A UA A200614105A UA A200614105 A UAA200614105 A UA A200614105A UA 85099 C2 UA85099 C2 UA 85099C2
Authority
UA
Ukraine
Prior art keywords
irinotecan
mol
preparation
closed
blood
Prior art date
Application number
UAA200614105A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кейсуке Йосино
Сигенори Нозава
Масаси Исозаки
Сейго Савада
Икуо Като
Original Assignee
Кабусики Кайся Якулт Хонса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кабусики Кайся Якулт Хонса filed Critical Кабусики Кайся Якулт Хонса
Publication of UA85099C2 publication Critical patent/UA85099C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к липосомам иринотекана. Липосома сформирована липидной мебраной, внешняя поверхность которой модифицирована гидрофильным полимером, а иринотекан инкапсулирован в концентрации по меньшей мере 0,1 мол./мол. (моль лекарственного средства/моль общего липида мембраны).
UAA200614105A 2004-06-01 2005-05-31 Liposomal irinotecan preparation UA85099C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01

Publications (1)

Publication Number Publication Date
UA85099C2 true UA85099C2 (en) 2008-12-25

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200614105A UA85099C2 (en) 2004-06-01 2005-05-31 Liposomal irinotecan preparation

Country Status (24)

Country Link
US (1) US7846473B2 (ru)
EP (1) EP1752150B1 (ru)
JP (1) JP4885715B2 (ru)
KR (1) KR100889139B1 (ru)
CN (1) CN1960729B (ru)
AP (1) AP2255A (ru)
AR (1) AR049137A1 (ru)
AU (1) AU2005249314B2 (ru)
BR (1) BRPI0511753A (ru)
CA (1) CA2567857C (ru)
CR (1) CR8768A (ru)
EA (1) EA011612B1 (ru)
EC (1) ECSP067041A (ru)
ES (1) ES2594621T3 (ru)
GE (1) GEP20094620B (ru)
IL (1) IL179558A0 (ru)
MX (1) MXPA06013874A (ru)
NO (1) NO20066074L (ru)
NZ (1) NZ551748A (ru)
TN (1) TNSN06395A1 (ru)
TW (1) TWI362931B (ru)
UA (1) UA85099C2 (ru)
WO (1) WO2005117878A1 (ru)
ZA (1) ZA200610204B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
US20090196918A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
JP2011520962A (ja) * 2008-05-19 2011-07-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 新規カチオン性脂質を含む方法及び組成物
JPWO2010058840A1 (ja) * 2008-11-20 2012-04-19 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
PL2508170T3 (pl) * 2009-12-03 2015-12-31 Jiangsu Hengrui Medicine Co Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
US10391056B2 (en) 2011-11-03 2019-08-27 Taiwan Lipsome Company, LTD. Pharmaceutical compositions of hydrophobic camptothecin derivatives
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014039504A1 (en) * 2012-09-04 2014-03-13 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
MX381475B (es) 2015-08-20 2025-03-12 Ipsen Biopharm Ltd Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
TWI778942B (zh) 2015-08-21 2022-10-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康（ｉｒｉｎｏｔｅｃａｎ）及奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）之組合療法治療轉移性胰臟癌的方法
JP6941606B2 (ja) 2015-10-16 2021-09-29 イプセン バイオファーム リミティド 安定化カンプトテシン医薬組成物
CN110402163A (zh) * 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
KR20240099264A (ko) 2021-10-15 2024-06-28 쿤샨 신윤다 바이오테크 컴퍼니 리미티드 항암제를 포함하는 조성물 및 이의 제조방법 및 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
IL142573A0 (en) 1998-09-16 2002-03-10 Alza Corp Liposome-entrapped topoisomerase inhibitors
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
WO2001000174A1 (fr) * 1999-06-25 2001-01-04 Terumo Kabushiki Kaisha Liposomes
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU7038501A (en) * 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
EP1432403B1 (en) * 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
CA2462369C (en) * 2001-10-03 2009-12-22 Celator Technologies Inc. Compositions for delivery of drug combinations
ES2387886T3 (es) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
ATE373466T1 (de) * 2001-11-13 2007-10-15 Celator Pharmaceuticals Inc Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
CA2527130A1 (en) * 2003-04-02 2004-10-14 Paul Tardi Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств

Also Published As

Publication number Publication date
NZ551748A (en) 2010-02-26
ES2594621T3 (es) 2016-12-21
TWI362931B (en) 2012-05-01
JPWO2005117878A1 (ja) 2008-04-03
TW200600095A (en) 2006-01-01
ZA200610204B (en) 2008-01-30
KR20070037440A (ko) 2007-04-04
US20080069868A1 (en) 2008-03-20
AU2005249314B2 (en) 2008-09-11
EA200602246A1 (ru) 2007-04-27
IL179558A0 (en) 2007-07-04
WO2005117878A1 (ja) 2005-12-15
AP2255A (en) 2011-07-21
NO20066074L (no) 2007-02-28
MXPA06013874A (es) 2007-04-25
EA011612B1 (ru) 2009-04-28
GEP20094620B (en) 2009-02-25
CA2567857A1 (en) 2005-12-15
US7846473B2 (en) 2010-12-07
ECSP067041A (es) 2006-12-29
CR8768A (es) 2007-08-28
AP2006003837A0 (en) 2006-12-31
CA2567857C (en) 2009-12-22
CN1960729A (zh) 2007-05-09
TNSN06395A1 (en) 2008-02-22
EP1752150B1 (en) 2016-08-31
KR100889139B1 (ko) 2009-03-17
AR049137A1 (es) 2006-06-28
EP1752150A1 (en) 2007-02-14
AU2005249314A1 (en) 2005-12-15
JP4885715B2 (ja) 2012-02-29
EP1752150A4 (en) 2012-06-20
BRPI0511753A (pt) 2008-01-02
CN1960729B (zh) 2012-04-11

Similar Documents

Publication Publication Date Title
UA85099C2 (en) Liposomal irinotecan preparation
Johnston et al. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin
Tsukamoto et al. Modulation of raft domains in a lipid bilayer by boundary-active curcumin
AU1999802A (en) Preparation of large liposomes by infusion into peg
TW200726485A (en) Liposomal delivery vehicle for hydrophobic drugs
AU4711296A (en) Method for loading lipid vesicles
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
WO2008109031A8 (en) Liposome carriers for in vivo delivery of fullerenes
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
WO2013008240A3 (en) Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
AU5314194A (en) Cosmetic delivery system for salicylic acid and process for preparation of the same
JPH07112968B2 (ja) リポソ−ム類における抗腫瘍剤類の被包
AU1724097A (en) Lipids and their use, for example, in liposomes
EP1163902A3 (en) Transdermal preparation containing hydrophilic or salt-form drug
Zhang et al. A novel method to prepare liposomes containing amikacin
ES2303114T3 (es) Metodo para cargar medicamentos en liposomas.
DE3476338D1 (en) Preparation of unilamellar large diameter liposomes, their pharmaceutical application in view of the encapsulation of the active principle for sustained release, and device therefor
AU2002340670A1 (en) Lipid carrier compositions and methods for improved drug retention
Margalit et al. Liposomal drug delivery: thermodynamic and chemical kinetic considerations
Efimova et al. Effect of cholesterol on the phase state and permeability of mixed liposomes composed of anionic diphosphatidylglycerol and zwitterionic dipalmitoylphosphatidylcholine
Bolard et al. Interaction of the anti-Candida amphotericin B (and other polyene antibiotics) with lipids
Bondeson et al. Promotion of acid-induced membrane fusion by basic peptides. Amino acid and phospholipid specificities
NO20054459L (no) Liposompreparat for reduksjon av liposomindusert komplementaktivering
CA2371483A1 (en) Liposome compositions for improved drug retention
De Wolf et al. Effect of doxorubicin on the order of the acyl chains of anionic and zwitterionic phospholipids in liquid-crystalline mixed model membranes: absence of drug-induced segregation of lipids into extended domains